Tarka is a drug owned by Abbvie Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 24, 2015. Details of Tarka's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5721244 | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs |
Feb, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Tarka is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tarka's family patents as well as insights into ongoing legal events on those patents.
Tarka's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tarka's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 24, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tarka Generic API suppliers:
Trandolapril; Verapamil Hydrochloride is the generic name for the brand Tarka. 1 company has already filed for the generic of Tarka. Check out the entire list of companies who have already received approval for Tarka's generic
How can I launch a generic of Tarka before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Tarka's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Tarka's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Tarka -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 2 mg/180 mg and 2 mg/240 mg | 09 Nov, 2007 | 1 | 26 May, 2010 | 24 Feb, 2015 | Eligible |
| 1 mg/240 mg | 20 Feb, 2008 | 1 | 30 Aug, 2010 | 24 Feb, 2015 | Eligible |
| 4 mg/ 240 mg | 24 Jul, 2007 | 1 | 05 May, 2010 | 24 Feb, 2015 | Eligible |
About Tarka
Tarka is a drug owned by Abbvie Inc. Tarka uses Trandolapril; Verapamil Hydrochloride as an active ingredient. Tarka was launched by Abbvie in 1996.
Approval Date:
Tarka was approved by FDA for market use on 22 October, 1996.
Active Ingredient:
Tarka uses Trandolapril; Verapamil Hydrochloride as the active ingredient. Check out other Drugs and Companies using Trandolapril; Verapamil Hydrochloride ingredient
Dosage:
Tarka is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG;180MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 4MG;240MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 2MG;240MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 1MG;240MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE | Discontinued | ORAL |